# Assembly Biosciences, Inc.: financial statements, quarterly

ASMB · Nasdaq · CIK 1426800 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asmb.md) · [Financials](/companies/asmb/financials.md) · [Filings](/companies/asmb/filings.md) · [Insiders](/companies/asmb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asmb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-123402.md) | [7.2 d](/filings/0000950170-25-042673.md) | [5.8](/filings/0000950170-25-066991.md) | [8.5](/filings/0000950170-25-104060.md) | [6.8](/filings/0001193125-25-274277.md) | [7.4 d](/filings/0001193125-26-115992.md) | [9.4](/filings/0001193125-26-211987.md) | [9.6](/filings/0001193125-26-349236.md) | [10.8](/filings/0001193125-25-274277.md) | [42.5 d](/filings/0001193125-26-115992.md) | [8.2](/filings/0001193125-26-211987.md) | [13.4](/filings/0001193125-26-349236.md) |
| Research and development | $m | [10.8](/filings/0000950170-24-123402.md) | [11.0 d](/filings/0000950170-25-042673.md) | [11.9](/filings/0000950170-25-066991.md) | [16.3](/filings/0000950170-25-104060.md) | [13.5](/filings/0001193125-25-274277.md) | [14.3 d](/filings/0001193125-26-115992.md) | [14.9](/filings/0001193125-26-211987.md) | [16.1](/filings/0001193125-26-349236.md) | [16.6](/filings/0001193125-25-274277.md) | [17.3 d](/filings/0001193125-26-115992.md) | [14.9](/filings/0001193125-26-211987.md) | [14.9](/filings/0001193125-26-349236.md) |
| Operating income | $m | [(15.0)](/filings/0000950170-24-123402.md) | [(12.6) d](/filings/0000950170-25-042673.md) | [(10.7)](/filings/0000950170-25-066991.md) | [(12.2)](/filings/0000950170-25-104060.md) | [(11.0)](/filings/0001193125-25-274277.md) | [(11.5) d](/filings/0001193125-26-115992.md) | [(9.9)](/filings/0001193125-26-211987.md) | [(11.1)](/filings/0001193125-26-349236.md) | [(10.9)](/filings/0001193125-25-274277.md) | [19.8 d](/filings/0001193125-26-115992.md) | [(11.4)](/filings/0001193125-26-211987.md) | [(6.3)](/filings/0001193125-26-349236.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-123402.md) | [0.0 d](/filings/0000950170-25-042673.md) | not reported | [0.4](/filings/0000950170-25-104060.md) | [0.0](/filings/0001193125-25-274277.md) | [(0.1) d](/filings/0001193125-26-115992.md) | not reported | [0.0](/filings/0000950170-25-104060.md) | [0.0](/filings/0001193125-25-274277.md) | [0.0 d](/filings/0001193125-26-115992.md) | not reported | not reported |
| Net income | $m | [(14.4)](/filings/0000950170-24-123402.md) | [(11.0) d](/filings/0000950170-25-042673.md) | [(9.1)](/filings/0000950170-25-066991.md) | [(11.2)](/filings/0000950170-25-104060.md) | [(9.6)](/filings/0001193125-25-274277.md) | [(10.3) d](/filings/0001193125-26-115992.md) | [(8.8)](/filings/0001193125-26-211987.md) | [(10.2)](/filings/0001193125-26-349236.md) | [(9.2)](/filings/0001193125-25-274277.md) | [22.1 d](/filings/0001193125-26-115992.md) | [(9.1)](/filings/0001193125-26-211987.md) | [(3.9)](/filings/0001193125-26-349236.md) |
| Diluted EPS | $ per share | [(3.29)](/filings/0000950170-24-123402.md) | not reported | [(1.66)](/filings/0000950170-25-066991.md) | [(1.98)](/filings/0000950170-25-104060.md) | [(1.51)](/filings/0001193125-25-274277.md) | not reported | [(1.17)](/filings/0001193125-26-211987.md) | [(1.33)](/filings/0001193125-26-349236.md) | [(0.72)](/filings/0001193125-25-274277.md) | not reported | [(0.54)](/filings/0001193125-26-211987.md) | [(0.20)](/filings/0001193125-26-349236.md) |
| Basic EPS | $ per share | [(3.29)](/filings/0000950170-24-123402.md) | not reported | [(1.66)](/filings/0000950170-25-066991.md) | [(1.98)](/filings/0000950170-25-104060.md) | [(1.51)](/filings/0001193125-25-274277.md) | not reported | [(1.17)](/filings/0001193125-26-211987.md) | [(1.33)](/filings/0001193125-26-349236.md) | [(0.72)](/filings/0001193125-25-274277.md) | not reported | [(0.54)](/filings/0001193125-26-211987.md) | [(0.20)](/filings/0001193125-26-349236.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [26.7](/filings/0000950170-23-061134.md) | [19.8](/filings/0000950170-25-042673.md) | [18.7](/filings/0000950170-24-055680.md) | [19.2](/filings/0000950170-24-093998.md) | [28.5](/filings/0000950170-24-123402.md) | [38.3](/filings/0001193125-26-115992.md) | [23.4](/filings/0000950170-25-066991.md) | [24.0](/filings/0000950170-25-104060.md) | [22.5](/filings/0001193125-25-274277.md) | [58.5](/filings/0001193125-26-349236.md) | [31.1](/filings/0001193125-26-211987.md) | [32.3](/filings/0001193125-26-349236.md) |
| Current assets | $m | [49.7](/filings/0000950170-23-061134.md) | [134](/filings/0000950170-25-042673.md) | [117](/filings/0000950170-24-055680.md) | [113](/filings/0000950170-24-093998.md) | [98.2](/filings/0000950170-24-123402.md) | [116](/filings/0001193125-26-115992.md) | [95.5](/filings/0000950170-25-066991.md) | [77.5](/filings/0000950170-25-104060.md) | [237](/filings/0001193125-25-274277.md) | [255](/filings/0001193125-26-349236.md) | [233](/filings/0001193125-26-211987.md) | [328](/filings/0001193125-26-349236.md) |
| Total assets | $m | [51.6](/filings/0000950170-23-061134.md) | [137](/filings/0000950170-25-042673.md) | [120](/filings/0000950170-24-055680.md) | [115](/filings/0000950170-24-093998.md) | [100](/filings/0000950170-24-123402.md) | [119](/filings/0001193125-26-115992.md) | [99.0](/filings/0000950170-25-066991.md) | [80.8](/filings/0000950170-25-104060.md) | [240](/filings/0001193125-25-274277.md) | [258](/filings/0001193125-26-349236.md) | [236](/filings/0001193125-26-211987.md) | [331](/filings/0001193125-26-349236.md) |
| Current liabilities | $m | [7.1](/filings/0000950170-23-061134.md) | [39.2](/filings/0000950170-25-042673.md) | [38.8](/filings/0000950170-24-055680.md) | [41.3](/filings/0000950170-24-093998.md) | [41.6](/filings/0000950170-24-123402.md) | [47.8](/filings/0001193125-26-115992.md) | [46.6](/filings/0000950170-25-066991.md) | [47.3](/filings/0000950170-25-104060.md) | [53.4](/filings/0001193125-25-274277.md) | [48.8](/filings/0001193125-26-349236.md) | [35.0](/filings/0001193125-26-211987.md) | [23.4](/filings/0001193125-26-349236.md) |
| Total liabilities | $m | [9.9](/filings/0000950170-23-061134.md) | [95.7](/filings/0000950170-25-042673.md) | [87.3](/filings/0000950170-24-055680.md) | [80.6](/filings/0000950170-24-093998.md) | [74.3](/filings/0000950170-24-123402.md) | [85.8](/filings/0001193125-26-115992.md) | [71.9](/filings/0000950170-25-066991.md) | [62.7](/filings/0000950170-25-104060.md) | [57.3](/filings/0001193125-25-274277.md) | [50.8](/filings/0001193125-26-349236.md) | [36.9](/filings/0001193125-26-211987.md) | [25.2](/filings/0001193125-26-349236.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [41.7](/filings/0000950170-24-123402.md) | [41.1](/filings/0001193125-26-115992.md) | [32.6](/filings/0000950170-25-104060.md) | [34.7](/filings/0001193125-25-274277.md) | [26.0](/filings/0001193125-25-274277.md) | [33.4](/filings/0001193125-26-349236.md) | [27.1](/filings/0001193125-26-349236.md) | [18.1](/filings/0001193125-26-349236.md) | [183](/filings/0001193125-25-274277.md) | [207](/filings/0001193125-26-349236.md) | [199](/filings/0001193125-26-349236.md) | [306](/filings/0001193125-26-349236.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.8) d](/filings/0000950170-24-123402.md) | [73.6 d](/filings/0000950170-25-042673.md) | [(18.4)](/filings/0000950170-25-066991.md) | [(17.1) d](/filings/0000950170-25-104060.md) | [(15.2) d](/filings/0001193125-25-274277.md) | [(0.4) d](/filings/0001193125-26-115992.md) | [(23.4)](/filings/0001193125-26-211987.md) | [(16.8) d](/filings/0001193125-26-349236.md) | [(15.1) d](/filings/0001193125-25-274277.md) | [14.2 d](/filings/0001193125-26-115992.md) | [(22.1)](/filings/0001193125-26-211987.md) | [(15.5) d](/filings/0001193125-26-349236.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-123402.md) | [0.1 d](/filings/0000950170-25-042673.md) | [0.0](/filings/0000950170-25-066991.md) | [0.0 d](/filings/0000950170-25-104060.md) | [0.0 d](/filings/0001193125-25-274277.md) | [0.0 d](/filings/0001193125-26-115992.md) | [0.0](/filings/0001193125-26-211987.md) | [0.0 d](/filings/0001193125-26-349236.md) | [0.0 d](/filings/0001193125-25-274277.md) | [0.0 d](/filings/0001193125-26-115992.md) | [0.0](/filings/0001193125-26-211987.md) | [0.0 d](/filings/0001193125-26-349236.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [48.4](/filings/0000950170-23-061134.md) | [4.3](/filings/0000950170-24-055680.md) | [4.4](/filings/0000950170-24-093998.md) | [4.4](/filings/0000950170-24-123402.md) | [5.5](/filings/0000950170-25-066991.md) | [5.6](/filings/0000950170-25-104060.md) | [6.4](/filings/0001193125-25-274277.md) | [7.5](/filings/0001193125-26-211987.md) | [7.7](/filings/0001193125-26-349236.md) | [12.7](/filings/0001193125-25-274277.md) | [16.9](/filings/0001193125-26-211987.md) | [18.9](/filings/0001193125-26-349236.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,360,596 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349236.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.